Breaking News & Announcements

Title: Cutting-edge Genetic Tests
Date: 04-Jun-2013
Description: Providing a wide range of Genetic testing such as CardioSURE (Heart and Stroke genetic test), LifeSURE (covers the lifetime risk of developing 115 major traits and diseases), BRACA1 & BRACA2 (Breast Cancer Genetic test) and MaterniT21 PLUS non-invasive, pre-natal diagnostic test.


Gribbles Pathology Goes One Step Further to Deliver Cutting-edge Genetic Tests

Gribbles, one of Asia and Australasia’s leading private pathology laboratories and Sengenics, a leading genetic diagnostics company has announced to make cutting-edge tests more accessible in Malaysia.

The partnership will focus on providing a wide range of Genetic testing such as:

  • CardioSURE (Heart and Stroke genetic test),
  • LifeSURE (covers the lifetime risk of developing 115 major traits and diseases),
  • BRACA1 & BRACA2 (Breast Cancer Genetic test) and
  • MaterniT21 PLUS non-invasive, pre-natal diagnostic test.

CardioSURE
Heart Disease and Stroke Genetic Test

CardioSURE is genetic test to assess the risk of heart disease and heart attack. A person’s DNA will never change and you will be required to conduct CardioSure once in your life time.

CardioSURE test can be taken at any age where one can assess the risk even before the symptoms of heart disease. CardioSURE Test is using cutting-edge genomics technologies to analyze the markers in DNA from the blood. The reporting of CardioSURE result is as proprietary Sengenics risk calculation matrix based on the presence or absence of mutations called SNPs (Single Nucleotide Polymorphisms).

16 markers tested in CardioSURE test includes: Factor V, Factor XIII, ProthrombinFactor XIII, Methylenetetrahydrofolate Reductase, Endothelial Nitric Oxide Synthase, Human Platelet Antigen 1, Plasminogen Activator Inhibitor 1, Endothelial Protein C Receptor, Lymphotoxin Alpha, Apolipoprotein B, Apolipoprotein E, Beta-Fibrinogen and Lymphotoxin Alpha Angiotensin-Converting Enzyme.


MaterniT21 PLUS
A Non-invasive Prenatal Test for Pregnant Women for Chromosomal Abnormalities

The MaterniT21 PLUS test analyzes circulating cell-free DNA extracted from a maternal blood sample. The test detects the relative amount of 21, 18, 13, X and Y chromosomal material. Parental testing for chromosomal abnormalities can help to determine whether the baby has certain genetic conditions such has Down Syndrome, Edwards Syndrome, Patau Syndrome and Sex Chromosomal Abnormalities (i.e. Turner Syndrome, Klinefelter Syndrome, Triple X and XYY Syndrome). Your doctor can recommend MaterniT21 Plus test as early as 10 weeks in your pregnancy. This test is available through your doctor.


 BRCA1 and BRCA2
Breast Cancer Genetic Test

Breast cancer is the second leading cause of cancer-related death in woman in Malaysia. About 5% to 10% of breast cancer cases are thought to be hereditary. BRCA1 and BRCA2 are human genes that belong to a class of genes known as tumour suppressors. Mutation of these genes has been linked to hereditary breast and ovarian cancer. A woman’s lifetime risk of developing breast and/or ovarian cancer is greatly increased if she inherits a harmful mutation in BCRA1 and BRCA2. A woman who has inherited a harmful mutation in BRCA1 and BRCA2 is about five times more likely to develop breast cancer than a woman who does not have such a mutation. Genetic tests are available to check for BRCA1 and BRCA2 mutations. If a harmful BRCA1 or BRCA2 mutation is found, several options are available to help a person manage their cancer risk. Early screening allow woman to make informed decision in taking steps to reduce their cancer risk.  

 

 

 

[ Back ] [ Print Friendly ]
 

Copyright © 2007 - 2021 Gribbles Pathology (M) Sdn Bhd. All Rights Reserved.

Powered by CORNERSTONE CONTENT MANAGEMENT SYSTEM